Literature DB >> 8212983

Cardiovascular risk factors in adult patients with growth hormone deficiency.

T Rosén1, S Edén, G Larson, L Wilhelmsen, B A Bengtsson.   

Abstract

Patients with adult onset growth hormone deficiency have a decreased life expectancy owing to an increased mortality from cardiovascular disease. In the present study, 104 subjects (66 men and 38 women, aged 22-74 years) with growth hormone deficiency and with adequate replacement therapy with glucocorticoids, thyroid hormones and gonadal steroids were studied with respect to known risk factors for cardiovascular disease. For comparison, data from a population study, "the MONICA study", were obtained. The patients had a significantly higher body mass index compared to controls (p < 0.001). Serum triglyceride concentration was higher (p < 0.001) but there was no difference in serum total cholesterol concentration. Serum high-density lipoprotein cholesterol concentration was lower (p < 0.001) in the patients. There was no difference in the prevalence of diabetes mellitus. The prevalence of treated hypertension was higher (p < 0.05) in the patients but the prevalence of smoking was lower (p < 0.001). Even after taking the increased body mass index into consideration, the changes in the prevalence of treated hypertension (p < 0.05) and in the serum concentrations of triglycerides (p < 0.05) and high-density lipoprotein concentrations (p < 0.001) remained. These results indicate that growth hormone deficiency alters lipoprotein metabolism and increases the risk for development of hypertension, which in turn might contribute to the increased risk for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212983     DOI: 10.1530/acta.0.1290195

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  40 in total

1.  Is vascular mortality increased in hypopituitarism?

Authors:  E M Erfurth; B Bülow; L E Hagmar
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

2.  Growth hormone deficiency in elderly patients with hypothalamo-pituitary tumors.

Authors:  A Colao; G Cerbone; R Pivonello; M Klain; G Aimaretti; A Faggiano; C Di Somma; M Salvatore; G Lombardi
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

Review 3.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

5.  Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Authors:  E Lin; T L Wexler; L Nachtigall; N Tritos; B Swearingen; L Hemphill; J Loeffler; B M K Biller; A Klibanski; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

6.  Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study.

Authors:  Catherine Beauregard; Andrea L Utz; Amber E Schaub; Lisa Nachtigall; Beverly M K Biller; Karen K Miller; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

7.  Changes in insulin levels following 6-month treatment with recombinant human growth hormone in growth hormone-deficient adults.

Authors:  D Valle; M N D Di Minno; V Palmieri; S Pezzullo; F Cirillo; C Di Somma; G Di Minno; G Lombardi
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

8.  Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort.

Authors:  Kerri A Nottage; Kirsten K Ness; Chenghong Li; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson
Journal:  Br J Haematol       Date:  2014-01-27       Impact factor: 6.998

9.  The decreased growth hormone response to growth hormone releasing hormone in obesity is associated to cardiometabolic risk factors.

Authors:  Fernando Cordido; Jesús Garcia-Buela; Susana Sangiao-Alvarellos; Teresa Martinez; Ovidio Vidal
Journal:  Mediators Inflamm       Date:  2010-01-21       Impact factor: 4.711

10.  Systemic hypertension counteracts potential benefits of growth hormone replacement therapy on left ventricular remodeling in adults with growth hormone deficiency.

Authors:  C de Gregorio; L Curtò; F Marini; G Andò; O Trio; F Trimarchi; S Coglitore; S Cannavò
Journal:  J Endocrinol Invest       Date:  2012-10-15       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.